IGF1R and pancreatic neoplasm: Tanzel et al. [30] identified that afatinib in combination with the insulin-like growth factor 1 receptor (IGF-IR) inhibitor NVP-AEW541 resulted in a synergistic growth inhibition of pancreatic cancer cells.